Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer

Clinical Breast Cancer · Published 2026-07-31 · DOI 10.1016/j.clbc.2026.07.003

Authors (5)

Esther G. Chong, Mengni Guo, Kevin Bera, Dani Castillo, Peter Wu

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Chong, E., Guo, M., Bera, K., et al. (2026). Evaluating the Efficacy of Neoadjuvant Endocrine Therapy in HER2-Low Versus HER2-Negative Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2026.07.003

Related articles

• Global Burdens and Trends of Breast Cancer Attributable to Dietary and Metabolic Risks: A 30-Year Analysis With Projections to 2050, Including Males and Females · Clinical Breast Cancer · 2026 · Same journal
• Effect of Treatment Sequencing in Older Adults With Early Breast Cancer. Insights From a Retrospective Single-Institution Cohort · Clinical Breast Cancer · 2026 · Same journal
• Patients With Luminal Breast Carcinoma: The State of the Field in Proteomic and Proteogenomic Molecular Subtyping · Clinical Breast Cancer · 2026 · Same journal
• Methodological Concerns Regarding the Assessment of Breast Cancer Risk Following Gender-Affirming Care · Clinical Breast Cancer · 2026 · Same journal
• Prevalence and Prognostic Implications of Circulating Tumor Cells Among Patients Undergoing Neoadjuvant Chemotherapy for Early-Stage Breast Cancer · Clinical Breast Cancer · 2026 · Same journal
• Association of Regional Anesthesia With Reduced Post-discharge Opioid Prescriptions Following Immediate Autologous Breast Reconstruction: An ACS-NSQIP Analysis · Clinical Breast Cancer · 2026 · Same journal
• Evaluation of Absorbable Hemostatic Powder on Post-operative Outcomes in Patients Undergoing Mastectomy · Clinical Breast Cancer · 2026 · Same journal
• Feasibility of Same Day Mastectomy Discharge in a Safety Net Hospital in Memphis, TN · Clinical Breast Cancer · 2026 · Same journal
• CTSG suppresses breast cancer progression by inhibiting the EGFR/ERK signaling pathway and enhancing CD8⁺ T cell activation · Clinical Breast Cancer · 2026 · Same journal
• The Xpert Breast Cancer Insight Test Predicts Distant Recurrence and Overall Survival in ER-Positive, HER2-Negative Early Breast Cancer · Clinical Breast Cancer · 2026 · Same journal